A New Era for Heart Transplants: Tech Upgrade Promises Longer Journeys

WALTHAM, Mass. – April 22, 2026 – Paragonix Technologies today announced a pivotal upgrade to its widely used organ transport system, a move that could significantly expand the reach and success of heart transplantation. The introduction of TempLock™ technology to its SherpaPak® Cardiac Transport System promises to give surgeons a more stable and reliable way to preserve donor hearts, directly addressing the growing challenge of transporting organs over longer distances.

Unveiled at the International Society for Heart and Lung Transplantation (ISHLT) 2026 conference, the enhancement is designed to maintain a donor heart within a strict, controlled temperature range of 4-8°C for extended periods. This innovation comes as ischemic times—the critical period an organ spends outside the body without blood supply—are increasing across the United States, forcing a reevaluation of traditional preservation methods.

A New Standard for a Race Against Time

For decades, the standard procedure for transporting a donor heart involved placing it in a commercial-grade cooler filled with ice. While simple, this method offers little control, exposing the delicate organ to unpredictable temperature fluctuations and the risk of freezing, which can cause irreversible cellular damage. This "ice age" of organ transport has long been a source of anxiety for transplant teams who work against a ticking clock.

Paragonix's SherpaPak system was designed to replace this uncertainty with precision. Building on its proprietary SherpaCool® phase-change technology, the system uses a nested canister design to suspend the organ in a sterile, cold preservation solution, shielding it from both physical shock and thermal injury. The new TempLock™ technology further refines this approach, optimizing the system's ability to hold a stable temperature for longer durations.

Clinical data has consistently shown the benefits of this controlled approach. Studies drawing from the GUARDIAN-Heart Registry, the world's largest clinical database focused on heart preservation, have demonstrated that using the SherpaPak system significantly reduces post-transplant complications compared to traditional ice storage. These include a reported 50% reduction in severe Primary Graft Dysfunction (PGD), a life-threatening condition where the new heart fails to function, and a 63% reduction in severe Right Ventricular Dysfunction.

Expanding the Gift of Life

The implications of more stable, long-duration preservation extend far beyond the operating room. By providing transplant teams with greater confidence and a wider time window, technologies like TempLock™ can fundamentally alter transplant logistics. This allows Organ Procurement Organizations (OPOs) to consider donor hearts from a much wider geographic area, breaking down barriers that previously made a long-distance match impossible.

This expansion is critical in the face of a persistent organ shortage. A larger donor pool means more potential matches for patients on the waiting list, offering hope where there was once only uncertainty.

Furthermore, the technology enables the safer use of "extended criteria" donor organs. These are hearts from donors who may be older or have other factors that would have previously made them too high-risk for transplantation. With advanced preservation mitigating some of those risks, surgeons can more confidently accept these life-saving organs. Studies have shown that the SherpaPak can help achieve positive outcomes even with longer ischemic times, sometimes exceeding four hours, which was once considered a major clinical barrier.

The Evolving Landscape of Organ Preservation

The TempLock™ launch highlights a broader industry shift away from static cold storage and toward more sophisticated preservation technologies. While Paragonix focuses on perfecting advanced static hypothermic preservation, the market also includes different approaches, such as machine perfusion (MP).

Systems like the TransMedics Organ Care System (OCS) use normothermic perfusion, keeping the heart beating and warm by circulating blood through it during transport. Other investigational methods, such as Hypothermic Oxygenated Perfusion (HOPE), circulate a cold, oxygenated solution. These active perfusion technologies represent a different paradigm, aiming to keep the organ in a near-physiologic state.

Paragonix's strategy, however, centers on providing a clinically proven, less complex, and widely adopted enhancement to the static cold storage method. With its devices used in over 10,000 transplants across more than 130 programs worldwide, the company has established a significant foothold. Its systems are FDA-cleared in the U.S. and recently secured approval under the stringent new European Union Medical Device Regulation (MDR), confirming its status in key international markets.

Data-Driven Confidence for Transplant Teams

A key element of Paragonix's approach is its emphasis on real-world data. The SherpaPak system is equipped with probes that continuously monitor internal temperature and track location, transmitting data in real-time to the transplant team. This layer of transparency and control provides invaluable peace of mind during the high-stakes journey from donor to recipient.

This data also feeds the ongoing GUARDIAN-Heart Registry. Peer-reviewed studies based on this registry have linked the use of the SherpaPak to remarkable improvements in patient survival—including a reported 72% reduction in one-year mortality and a 68% reduction in two-year mortality compared to ice storage. Patients have also seen a significant increase in freedom from rehospitalization in the year following their transplant.

“The evolution of the SherpaPak System is grounded in what matters most to transplant teams - reliability, consistency, and confidence in preservation conditions,” said Dr. Lisa Anderson, President of Paragonix Technologies, in the announcement. “TempLock represents our continued focus on delivering every possible advantage when it matters most.”

This commitment to continuous, data-backed innovation reflects a new era in transplantation, where engineering precision works in concert with clinical expertise. As transplant medicine pushes new boundaries, the technology that protects the precious gift of a donor organ is proving to be just as critical as the surgeon's skill in the operating room. The goal is to ensure that every donated organ is given the best possible chance to provide a new lease on life.